Type 1 Diabetes

Discover key advancements in endocrinology from July 2025, including FDA approvals and trial results.

Isaacs and Bellini walk through the newly released Preexisting Diabetes in Pregnancy guidelines, discussing each of the 10 recommendations.

Isaacs and Bellini discuss the highlights of the Endocrine Society’s annual meeting, from upcoming treatments to public education.

Shah discusses the stagnation of the T1D treatment landscape and the potential progress that GLP-1 RA research could present.

Philis-Tsimikas emphasized the impact of nonmedical factors on health and how clinicians can be cognizant of them in their patient management.

Shah discusses the results from the ADJUST-T1D trial comparing semaglutide to placebo, which saw a significant disparity in semaglutide’s favor.

June 2025 highlights groundbreaking advancements in endocrinology, featuring key insights from major conferences on diabetes, heart health, and kidney care.

From uncovering new benefits of semaglutide to targeting hypercortisolism in people with type 2 diabetes, here are 5 key updates from the annual meeting.

Donovan and Feig shared exciting findings and further research from a study evaluating an insulin pump with Control-IQ technology with Dexcom G6 sensor.

Berry discussed findings from a retrospective, real-world study but emphasized that they should be confirmed in randomized controlled trials.

A new study reveals hybrid closed-loop technology significantly improves glucose control for pregnant women with T1D.

Automated insulin delivery systems enhance blood glucose control for pregnant women with type 1 diabetes, potentially advancing diabetes care.

Most participants (83%) did not require exogenous insulin 1 year after zimislecel (VX-880) infusion.

An overview of 7 presentations included as late-breaking clinical trials at ADA 2025.

Stay updated with the latest healthcare breakthroughs, including weight loss treatments, pediatric therapies, and FDA approvals shaping the future of medicine.

Adult-onset T1D significantly raises cardiovascular disease and mortality risks, highlighting the need for improved management and prevention strategies.

In this episode, hosts explore updates on continuous glucose monitoring (CGM) systems from April 2025.

Our April 2025 month in review highlights significant advancements in endocrinology, including innovative therapies and FDA approvals that enhance diabetes management.

In this episode, hosts explore the findings of the Catalyst trial on hypercortisolism and its impact on type 2 diabetes.

In this episode, hosts explore promising results of orforglipron, a new oral GLP-1 receptor agonist, showing significant A1C reduction and weight loss potential.

Once-daily orforglipron showed strong efficacy and safety, matching injectable GLP-1s for A1c reduction and weight loss in the ACHIEVE-1 trial.

In this episode, experts discuss practical guidance for screening for presymptomatic type 1 diabetes with Rifka Schulman-Rosenbaum, MD.

With regulatory clearance for people aged ≥18 years with diabetes, Dexcom G7 boasts the longest-lasting wearable and most accurate CGM system.

In the first of 2 episodes spotlighting the meeting, hosts break down news and updates from the Advanced Technologies and Treatments for Diabetes meeting.

Our Q1 2025 recap for endocrinology spotlights 5 regulatory updates, 5 key trial announcements, and top expert perspectives in diabetes care.